BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

Novartis to pay $678M in kickbacks settlement  Novartis AG (NYSE:NVS; SIX:NOVN) will pay $678 million and, under a corporate integrity agreement, conduct its speaker programs virtually for the next five years after the pharma reached...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene as CFO; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and moreBy Robin Sawka, BioCentury Staff

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | Jun 22, 2020
Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

Codiak is extending its exosome platform to AAVs by partnering with Sarepta to overcome two major obstacles for nucleic acid therapies: tissue-targeting and repeat dosing. The resulting products would be vectors within vectors, with multiple...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

A first from Ultragenyx in a rare disease  FDA approved Crysvita burosumab-twza from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat tumor-induced osteomalacia in patients age two and older. The anti-FGF23 mAb is the first to be...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | Jun 8, 2020
Product Development

Sarepta heading toward pivotal trial of first limb-girdle muscular dystrophy gene therapy

A new readout clears the path for Sarepta to move ahead next year with a pivotal study of its gene therapy for limb-girdle muscular dystrophy type 2E, one of several LGMD subtypes the company is...
BioCentury | May 15, 2020
Product Development

12-month data set up Pfizer DMD gene therapy for Phase III, but SAEs may give Sarepta safety edge

Pfizer believes encouraging long-term efficacy data and recently installed protocols for mitigating adverse events will help the pharma advance its DMD gene therapy into Phase III testing within the next few months as it ramps...
BioCentury | May 11, 2020
Emerging Company Profile

Dyno taking partner-heavy strategy with next-generation gene therapy vectors

After two years in stealth mode, modestly-funded Dyno believes its synthetic capsid engineering platform will be best used by partners to feed their gene therapy pipelines with optimized candidates -- including two biopharmas that have...
BioCentury | Apr 29, 2020
Product Development

Clover becomes latest COVID-19 vaccine developer to gain CEPI funding as Moderna, Jenner continue to advance

Amid a flurry of COVID-19 vaccine updates, CEPI has announced an investment in Clover that will support its advancement into the clinic. On the treatment front, Pneumagen reported preclinical antiviral activity for its lead program,...
Items per page:
1 - 10 of 707
BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

Novartis to pay $678M in kickbacks settlement  Novartis AG (NYSE:NVS; SIX:NOVN) will pay $678 million and, under a corporate integrity agreement, conduct its speaker programs virtually for the next five years after the pharma reached...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene as CFO; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and moreBy Robin Sawka, BioCentury Staff

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | Jun 22, 2020
Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

Codiak is extending its exosome platform to AAVs by partnering with Sarepta to overcome two major obstacles for nucleic acid therapies: tissue-targeting and repeat dosing. The resulting products would be vectors within vectors, with multiple...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

A first from Ultragenyx in a rare disease  FDA approved Crysvita burosumab-twza from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat tumor-induced osteomalacia in patients age two and older. The anti-FGF23 mAb is the first to be...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | Jun 8, 2020
Product Development

Sarepta heading toward pivotal trial of first limb-girdle muscular dystrophy gene therapy

A new readout clears the path for Sarepta to move ahead next year with a pivotal study of its gene therapy for limb-girdle muscular dystrophy type 2E, one of several LGMD subtypes the company is...
BioCentury | May 15, 2020
Product Development

12-month data set up Pfizer DMD gene therapy for Phase III, but SAEs may give Sarepta safety edge

Pfizer believes encouraging long-term efficacy data and recently installed protocols for mitigating adverse events will help the pharma advance its DMD gene therapy into Phase III testing within the next few months as it ramps...
BioCentury | May 11, 2020
Emerging Company Profile

Dyno taking partner-heavy strategy with next-generation gene therapy vectors

After two years in stealth mode, modestly-funded Dyno believes its synthetic capsid engineering platform will be best used by partners to feed their gene therapy pipelines with optimized candidates -- including two biopharmas that have...
BioCentury | Apr 29, 2020
Product Development

Clover becomes latest COVID-19 vaccine developer to gain CEPI funding as Moderna, Jenner continue to advance

Amid a flurry of COVID-19 vaccine updates, CEPI has announced an investment in Clover that will support its advancement into the clinic. On the treatment front, Pneumagen reported preclinical antiviral activity for its lead program,...
Items per page:
1 - 10 of 707